Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.An affiliate of Iroko Pharmaceuticals has signed a licensing agreement with EMS for the exclusive rights to market and sell Zorvolex (diclofenac) capsules in Brazil.
Subscribe to our email newsletter
The Brazilian pharmaceutical firm EMS will be responsible for securing regulatory and pricing approval, as well as the marketing and supply of the medication, in that territory.
In October 2013, the US Food and Drug Administration (FDA) approved Zorvolex to treat mild to moderate acute pain in adults and is now available by prescription.
The company said that Zorvolex is currently not approved for marketing in any other country and will continue to retain all marketing rights to Zorvolex in the US.
Iroko Pharmaceuticals president and CEO John Vavricka said, "This new strategic partnership will allow us to utilize the expertise and knowledge of EMS to further expand access and availability of ZORVOLEX to regions outside of the United States where patients continue to have needs for additional treatment options for acute pain."
In 2013, Iroko entered into strategic agreements with Algorithm and PT Pratapa Nirmala (Fahrenheit), under which the two firms secured exclusive rights to market and sell Zorvolex in countries in the Middle East, North Africa (MENA) region and Indonesia, respectively.
EMS vice president of Institutional Marketing Marcus Sanchez said: "Expanding EMS’s operations into innovation-driven segments is a strategy defined by EMS in order to maintain its differentiation in the Brazilian market and its leadership position."